Novo Nordisk has entered a strategic partnership with OpenAI to integrate AI systems across its research, manufacturing, and commercial workflows. Initial pilot programs are expected across R&D, manufacturing, and commercial units, with broader rollout planned through 2026.
Novo plans to deploy AI tools across the full value chain, from early target identification and hypothesis generation to supply chain management and distribution, potentially shortening drug development timelines. In…
